Sonoma Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

9. Significant Customer Concentrations

9. Significant Customer Concentrations	3 Months Ended
Jun. 30, 2013
Risks and Uncertainties [Abstract]
9. Significant Customer Concentrations	For the three months ended June 30, 2013, one customer represented 42%, and one customer represented 22% of the quarter’s revenue. For the three months ended June 30, 2012, one customer represented 28% of the quarter’s revenue. At June 30, 2013, one customer represented 39%, and one customer represented 28% of the net accounts receivable balance. At March 31, 2013, one customer represented 34%, one customer represented 26%, and one customer represented 15% of the net accounts receivable balance.

9. Significant Customer Concentrations

3 Months Ended

Jun. 30, 2013

For the three months ended June 30, 2013, one customer represented 42%, and one customer represented 22% of the quarter’s revenue. For the three months ended June 30, 2012, one customer represented 28% of the quarter’s revenue.

At June 30, 2013, one customer represented 39%, and one customer represented 28% of the net accounts receivable balance. At March 31, 2013, one customer represented 34%, one customer represented 26%, and one customer represented 15% of the net accounts receivable balance.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References + Details